Showing 15 posts of 128 posts found.

BMS receives $625 million patent settlement boost from Merck

January 23, 2017
Sales and Marketing BMS, MSD, Merck, keytruda, opdivo

Bristol-Myers Squibb were in desperate need of releasing good news after the brief announcement that it would no longer be …

MSD and Lilly announce immuno-oncology collaboration

January 11, 2017
Medical Communications, Research and Development Eli Lilly, Lartruvo, MSD, keytruda, lilly

MSD, known as Merck in North America, and Eli Lilly have announced the expansion of their existing immuno-oncology collaboration. The …


MSD looks to jump the gun with combination immunotherapy application

January 11, 2017
Research and Development, Sales and Marketing AstraZeneca, BMS, MSD, Roche, immunotherapy, keytruda

MSD, known as Merck in North America, has launched a bold move by filing Keytruda, and being accepted, for Priority …


NICE approves MSD’s Keytruda for new cancer indication

December 1, 2016
Medical Communications, Sales and Marketing MSD, NICE, keytruda

The National Institute of Health and Care Excellence (NICE) has announced its recommendation of MSD’s immunotherapy drug Keytruda (pembrolizumab) for …


MSD’s Keytruda given first FDA approval for first line treatment

October 25, 2016
Manufacturing and Production BMS, MSD, NSCLC, keytruda, opdivo

MSD, known as Merck in the US, has scored a big success in treating non-small cell lung cancer (NSCLC), with …


MSD’s Keytruda early success ends trial early

October 24, 2016
Sales and Marketing MSD, Merck, Roche, keytruda, opdivo, tecentriq

MSD, known as Merck in the US, ended their Phase III trial of Keytruda for treatment of advanced urothelial cancer …


Failure for BMS’ Opdivo in lung cancer trial

October 10, 2016
Research and Development, Sales and Marketing BMS, MSD, Roche, clinical trial failure, keytruda, opdivo, tecentriq

Disappointing news for Bristol-Myers Squibb as the company announced that its blockbuster drug Opdivo (nivolumab) failed to meet its primary …


MSD’s Keytruda twice as successful against standard therapy for lung cancer

October 10, 2016
Sales and Marketing Bristol-Myers Squibb, MSD, Merck, keytruda

MSD, known as Merck in North America, released data that displayed the success of their drug, Keytruda, in a 123-patient …


Merck’s Keytruda suffers rejection at hands of NICE

October 5, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing MSD, Merck, NHS, NICE, keytruda

NICE rejected Merck’s Keytruda, a treatment for advanced non-small-cell lung cancer (NSCLC), on the basis that the drug was not …


FDA to review MSD’s Keytruda as a first-line lung cancer treatment

September 7, 2016
Research and Development FDA, MSD, Merck, first-line, keytruda, lung cancer, non-small cell lung cancer, opdivo

The US Food and Drug Administration has accepted the supplemental biologics license application from MSD, known as Merck in the …


Roche’s Tecentriq meets primary endpoints in Phase III lung cancer trial

September 1, 2016
Research and Development PD-L1, Roche, keytruda, nivolumab, opdivo, phase III, tecentriq

Roche has presented new Phase III data for cancer immunotherapy Tecentriq (atezolizumab), which shows a clinically meaningful improvement in overall …


FDA approves MSD’s Keytruda for head and neck cancer treatment

August 8, 2016
Manufacturing and Production, Research and Development Cancer, FDA, MSD, keytruda

The US Food and Drug Administration (FDA) has approved MSD’s Keytruda (pembrolizumab) for treatment of recurrent or metastatic head and …


Opdivo and Keytruda set for India launches by end of year

August 8, 2016
Sales and Marketing India, keytruda, launch, opdivo

Indian cancer patients could be set to receive two of the world’s leading oncology drugs, MSD’s Keytruda and Bristol-Myers Squibb’s …


MSD scores EU approval for Keytruda in lung cancer

August 3, 2016
Research and Development, Sales and Marketing EU, MSD, Merck, approval, keytruda, lung cancer

MSD, called Merck in the US and Canada, has announced that the European Commission has approved Keytruda (pembrolizumab) for patients …


UK medical charity sells part of interest in MSD’s Keytruda for $150 million

July 15, 2016
Research and Development, Sales and Marketing MSD, Merck, keytruda

UK medical research charity MRC Technology sold part of its royalty interest in US pharma major MSD’s (NYSE: MRK) immunotherapy …

Latest content